To achieve the goals set out in its 'Vision 2030', argenx has set the following priorities for 2025: Expand the global VYVGART opportunity by reaching more patients broadly across MG, CIDP and ITP ...

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

As states on the NHS inform website, coeliac disease is a common autoimmune condition where the immune system in a person’s ...

The NHS has issued a warning that persistent bloating, despite lifestyle changes such as dieting or exercising, could be a ...

Immune globulin (human) is under clinical development by Octapharma and currently in Phase III for Unspecified Neurologic Disorders.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) ...

Bacterial immune evasion is the process by which bacteria avoid and antagonize the bacterial host response, which is mediated by the host's immune system. Here, the authors show that vaginal ...

blocker approved for the treatment of chronic inflammatory demyelinating polyneuropathy or CIDP. CIDP is a progressive, immune-mediated rare and debilitating neuromuscular disorder of the ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

Immune globulin (human) is under clinical development by Octapharma and currently ... Panzyga is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to ...